Top Markets
Coin of the day
Affimed N.V. Affimed N.V.

Affimed N.V.

AFMD
Ранг среди акций #36349
Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise,... Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts on the identification and advancement of innovative cancer immunotherapies across the United States, Germany, and the broader European region. A key asset in their development pipeline is AFM13. This candidate has successfully concluded its Phase II clinical study for peripheral T-cell lymphoma and is currently progressing through Phase IIa trials for CD30-positive lymphoma, alongside a Phase I trial for Hodgkin lymphoma. Beyond AFM13, Affimed is actively developing several other therapeutic candidates. These include AFM24, a distinctive tetravalent, bispecific innate cell engager designed to target both epidermal growth factor receptor (EGFR) and CD16A; it is presently undergoing Phase IIa clinical trials for a range of advanced cancers. Further back in the pipeline are AFM28, an innate cell engager (ICE) in preclinical development for acute myeloid leukemia, and AFM32, another ICE candidate also in preclinical stages, aimed at solid tumors. The company has forged strategic collaboration agreements with prominent institutions such as The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd. Moreover, it benefits from a research funding agreement with The Leukemia & Lymphoma Society. Founded in 2000 and headquartered in Heidelberg, Germany, the organization transitioned its name to Affimed N.V. in October 2014, having previously operated as Affimed Therapeutics B.V.
Цена акции
$0.1815
Последняя синхронизация: 2026-04-06
Рыночная капитализация
$2.78M
Изменение (1 день)
0.00%
Изменение (1 год)
365.38%
Страна
DE
Торговля Affimed N.V. (AFMD)

Категория

EPS для Affimed N.V. (AFMD)
EPS по состоянию на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Affimed N.V., текущий EPS компании (TTM) составляет 0. В конце 2026 EPS компании составлял 0, равна показателю 2026 года, равному 0.
История EPS компании Affimed N.V. с 2026 по 2026
EPS на конец каждого года
Год EPS Изменить
Недостаточно данных для указанных дат.
EPS для аналогичных компаний или конкурентов
Компания EPS Разница в EPS Страна
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE